

Chiara Gabellini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5049962/publications.pdf>

Version: 2024-02-01

37
papers

1,277
citations

304602

22
h-index

454834

30
g-index

39
all docs

39
docs citations

39
times ranked

2338
citing authors

#	ARTICLE	IF	CITATIONS
1	Exposure to the natural alkaloid Berberine affects cardiovascular system morphogenesis and functionality during zebrafish development. <i>Scientific Reports</i> , 2020, 10, 17358.	1.6	10
2	Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 103.	3.5	5
3	SETD5 Regulates Chromatin Methylation State and Preserves Global Transcriptional Fidelity during Brain Development and Neuronal Wiring. <i>Neuron</i> , 2019, 104, 271-289.e13.	3.8	75
4	Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 405.	3.5	29
5	Interleukin 8 mediates bcl-2-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model. <i>International Journal of Cancer</i> , 2018, 142, 584-596.	2.3	51
6	Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain. <i>Carcinogenesis</i> , 2017, 38, 579-587.	1.3	39
7	BCL-XL overexpression promotes tumor progression-associated properties. <i>Cell Death and Disease</i> , 2017, 8, 3216.	2.7	76
8	Abstract 933: Bcl-xL overexpression promotes tumor aggressiveness. , 2017, , .		0
9	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1471-1491.	2.9	60
10	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. <i>Oncotarget</i> , 2016, 7, 11332-11348.	0.8	49
11	Abstract 2324: The histone acetyltransferase inhibitor CPTH6 selectively targets lung cancer stem-like cells. , 2015, , .		0
12	Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. <i>Molecular Cancer</i> , 2014, 13, 230.	7.9	51
13	Abstract 1684: Histone deacetylase inhibition enhances Pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer models. , 2014, , .		0
14	Abstract 77: bcl-xL protein overexpression enhances tumor progression of human melanoma cells in zebrafish xenograft model: Involvement of CXCL8 chemokine. , 2014, , .		0
15	Removal of the BH4 Domain from Bcl-2 Protein Triggers an Autophagic Process that Impairs Tumor Growth. <i>Neoplasia</i> , 2013, 15, 315-IN37.	2.3	29
16	BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition. <i>Carcinogenesis</i> , 2013, 34, 2558-2567.	1.3	23
17	The thiazole derivative CPTH6 impairs autophagy. <i>Cell Death and Disease</i> , 2013, 4, e524-e524.	2.7	28
18	CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells. <i>Clinical Cancer Research</i> , 2012, 18, 475-486.	3.2	47

#	ARTICLE	IF	CITATIONS
19	Scriptaid effects on breast cancer cell lines. <i>Journal of Cellular Physiology</i> , 2012, 227, 3426-3433.	2.0	26
20	Abstract LB-82: Modulation of autophagic flux by CPTH6, a Gcn5/pCAF histone acetyltransferase inhibitor with antitumoral activity. , 2012, , .		0
21	Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. <i>Cell Death and Differentiation</i> , 2011, 18, 1024-1035.	5.0	53
22	Abstract 16: Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. , 2011, , .		0
23	Bcl-2 Regulates HIF-1 β Protein Stabilization in Hypoxic Melanoma Cells via the Molecular Chaperone HSP90. <i>PLoS ONE</i> , 2010, 5, e11772.	1.1	72
24	478 Bcl-2 regulates HIF-1 α protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90 β . <i>European Journal of Cancer, Supplement</i> , 2010, 8, 153.	2.2	2
25	Toll-like Receptor 3 Regulates Angiogenesis and Apoptosis in Prostate Cancer Cell Lines through Hypoxia-Inducible Factor 1 β . <i>Neoplasia</i> , 2010, 12, 539-549.	2.3	85
26	Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. <i>European Journal of Cancer</i> , 2009, 45, 2618-2627.	1.3	121
27	Involvement of nuclear factor κ B in bcl α -induced interleukin 8 expression in glioblastoma. <i>Journal of Neurochemistry</i> , 2008, 107, 871-882.	2.1	41
28	Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression. <i>Molecular Cancer Research</i> , 2007, 5, 761-771.	1.5	41
29	Involvement of RB gene family in tumor angiogenesis. <i>Oncogene</i> , 2006, 25, 5326-5332.	2.6	47
30	p27kip1 overexpression promotes paclitaxel-induced apoptosis in pRb-defective SaOs-2 cells. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 1645-1652.	1.2	5
31	The involvement of oxidative stress in bovine herpesvirus type 4-mediated apoptosis. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 2106.	3.0	14
32	pRb2/p130 Decreases Sensitivity to Apoptosis Induced by Camptothecin and Doxorubicin but not by Taxol. <i>Clinical Cancer Research</i> , 2004, 10, 8085-8093.	3.2	11
33	?-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. <i>International Journal of Cancer</i> , 2003, 104, 243-250.	2.3	72
34	Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells. <i>Molecular Pharmacology</i> , 2003, 63, 632-638.	1.0	27
35	Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1. <i>British Journal of Cancer</i> , 2003, 89, 1091-1095.	2.9	5
36	C-Myc Down-Regulation Increases Susceptibility to Cisplatin through Reactive Oxygen Species-Mediated Apoptosis in M14 Human Melanoma Cells. <i>Molecular Pharmacology</i> , 2001, 60, 174-182.	1.0	82

#	ARTICLE	IF	CITATIONS
37	A nanogenetic approach to genome editing. , 0, , .		0